| Transaction Date | Recipient | Shares | Type | Price | Value |
|---|---|---|---|---|---|
| 14th January 2021 | Trevor Hallam | 19,405 | Exercise of derivative | $4.36 | $84,605.80 |
| 28th December 2020 | Trevor Hallam | 2,393 | Exercise of derivative | $4.36 | $10,433.48 |
| 28th December 2020 | Trevor Hallam | 2,393 | Open or private sale | $22.37 | $53,530.21 |
| 10th December 2020 | John Gordon Freund | 118,735 | Other acquisition or disposition | $0.00 | |
| 10th December 2020 | John Gordon Freund | 56,327 | Other acquisition or disposition | $0.00 | |
| 3rd December 2020 | John Gordon Freund | 47,886 | Open or private sale | $23.39 | $1,120,197.20 |
| 2nd December 2020 | John Gordon Freund | 100,000 | Open or private sale | $23.28 | $2,328,480.00 |
| 27th November 2020 | Trevor Hallam | 2,393 | Exercise of derivative | $4.36 | $10,433.48 |
| 27th November 2020 | Trevor Hallam | 2,393 | Open or private sale | $17.01 | $40,713.07 |
| 5th November 2020 | Trevor Hallam | 16,751 | Exercise of derivative | $4.36 | $73,034.36 |
Sutro Biopharma
Based on disclosure changes, sentiment, insider trading and news impact we give a rating of 4/10.
Sutro Biopharma Inc. engages in the drug discovery, development and manufacturing of pharmaceutical products. Its products technologies include XpressCF, anti-body drug conjugates, bispecifics & engineered antibodies and cGMP facility.
Ticker: STRO
Sector: Health Technology
Industry: Pharmaceuticals: Major
SEC Central Index Key (CIK): 1382101
Employees: 168
Exchange: NASDAQ
Auditor Opinion:
You must Login to see Language Changes
Disclosure Language changes
You must Login to see analysis
Red Flags
Revenue From Related Parties of $0 for the period Apr 2020 to Jun 2020 in the context of all up
Revenue From Related Parties of $3 M for the period Jan 2020 to Jun 2020 in the context of all up
Revenue From Related Parties of $3 M for the period Jan 2020 to Jun 2020 in the context of Merck sharp and dohme corporation
Revenue From Related Parties of $5 M for the period Apr 2019 to Jun 2019 in the context of all up
Revenue From Related Parties of $10 M for the period Jan 2019 to Jun 2019 in the context of all up
Fundamentals
Cash at Carrying Value: $65 M (0%)
Marketable Securities, Current: $136 M (20%)
Assets, Current: $258 M (101%)
Property, Plant and Equipment, Net: $11 M (16%)
Other Assets, Noncurrent: $2 M (-16%)
Assets: $278 M (77%)
Accounts Payable, Current: $5 M (-12%)
Accrued Liabilities, Current: $5 M (-24%)
Liabilities, Current: $35 M (7%)
Long-term Debt, Excluding Current Maturities: $24 M (173%)
Other Liabilities, Noncurrent: $148 Th (10%)
Liabilities: $71 M (20%)
Common Stock, Value, Issued: $36 Th (56%)
Common Stock, Shares, Issued: $36 M (55%)
Additional Paid in Capital, Common Stock: $392 M (33%)
Retained Earnings (Accumulated Deficit): $185 M (0%)
Accumulated Other Comprehensive Income (Loss), Net of Tax: $398 Th (141%)
Stockholders' Equity (Parent): $207 M (0%)
Liabilities and Equity: $278 M (77%)
Revenue: $9 M (-43%)
Research and Development: $17 M (-50%)
General and Administrative Expenses: $9 M (-50%)
Operating Income/Loss: $16 M (-53%)
EPS (basic): $1 (0%)
EPS (diluted): $0.94 (0%)
News
Sutro Biopharma (STRO) Investor Presentation - Slideshow
9th December 2020
DXP Enterprises Reports Third Quarter 2020 Results
6th November 2020
17 Arrested For Running Fake Call Centre In Delhi: Police
6th November 2020
Ubiquiti Inc. Reports First Quarter Fiscal 2021 Financial Results
6th November 2020